Failure of insulin and glucagon infusion to stimulate liver regeneration in fulminant hepatic failure

Philip M. Harrison, Robin D. Hughes, Alistair Forbes, Bernard Portmann, Graeme J. M. Alexander, Roger Williams

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


A randomised controlled trial of insulin and glucagon infusion was carried out in 18 patients in grade III or IV coma from fulminant hepatic failure due to viral or drug-induced hepatic necrosis to see whether mortality could be reduced by stimulating hepatic regeneration. Nine patients received a continuous infusion of insulin 3 U/h and glucagon 200 micrograms/h made up in 5% dextrose containing 1% human albumin solution (HAS) while controls received 5% dextrose and HAS alone. Baseline plasma insulin and glucagon levels were comparably raised in both groups and, on infusion, rose significantly higher in the insulin- and glucagon-treated patients compared to controls. Two control and one treated patient recovered. Median survival time from enrolment to death was similar for insulin- and glucagon-treated patients and controls--2 and 3 days, respectively. Insulin and glucagon therapy did not enhance hepatic synthetic function, as measured by a fall in prothrombin time or a rise in alpha-fetoprotein; nor did it stimulate hepatic regeneration, only one patient in each group showed histological evidence of hepatic regeneration at post-mortem.
Original languageEnglish
Pages (from-to)332-336
Number of pages5
JournalJournal of Hepatology
Issue number3
Publication statusPublished - May 1990


  • Adult
  • Aged
  • Female
  • Glucagon
  • Humans
  • Infusions, Intravenous
  • Insulin
  • Liver
  • Liver Diseases
  • Liver Regeneration
  • Male
  • Middle Aged
  • Randomized Controlled Trials as Topic

Cite this